OraSure Technologies, Inc. (OSUR) Shares Bought by Bank of Montreal Can
Bank of Montreal Can boosted its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 102.8% during the second quarter, Holdings Channel reports. The firm owned 143,295 shares of the medical instruments supplier’s stock after buying an additional 72,644 shares during the period. Bank of Montreal Can’s holdings in OraSure Technologies were worth $2,472,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. purchased a new stake in OraSure Technologies during the first quarter worth $100,000. Private Advisor Group LLC increased its stake in OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the period. Profund Advisors LLC purchased a new stake in OraSure Technologies during the first quarter worth $137,000. BNP Paribas Arbitrage SA increased its stake in OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 9,723 shares during the period. Finally, Capital Fund Management S.A. purchased a new stake in OraSure Technologies during the first quarter worth $144,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) traded down 1.91% during midday trading on Thursday, hitting $20.54. The stock had a trading volume of 271,785 shares. The stock has a market cap of $1.20 billion, a PE ratio of 37.97 and a beta of 1.57. The stock has a 50-day moving average of $18.17 and a 200 day moving average of $13.95. OraSure Technologies, Inc. has a 52 week low of $6.53 and a 52 week high of $21.59.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. The company had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $0.07 earnings per share. Analysts anticipate that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.
A number of equities research analysts have weighed in on OSUR shares. BidaskClub downgraded OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Canaccord Genuity upped their target price on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Jefferies Group LLC upped their target price on OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Saturday, May 6th. Finally, Stephens restated an “overweight” rating and issued a $19.00 target price (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $15.46.
In other news, CFO Ronald H. Spair sold 510,112 shares of OraSure Technologies stock in a transaction on Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now directly owns 208,606 shares of the company’s stock, valued at $4,309,799.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ronny B. Lancaster sold 89,684 shares of OraSure Technologies stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total transaction of $1,326,426.36. Following the transaction, the director now directly owns 6,295 shares in the company, valued at $93,103.05. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,036,670 shares of company stock worth $19,807,152. Insiders own 7.80% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.